Low renal replacement therapy incidence among slowly progressing elderly chronic kidney disease patients referred to nephrology care: an observational study by unknown
RESEARCH ARTICLE Open Access
Low renal replacement therapy incidence
among slowly progressing elderly chronic
kidney disease patients referred to
nephrology care: an observational study
Ulrika Hahn Lundström1†, Alessandro Gasparini1†, Rino Bellocco2,3, Abdul Rashid Qureshi1,
Juan-Jesus Carrero1,4 and Marie Evans1,5*
Abstract
Background: Elderly patients with advanced chronic kidney disease (CKD) have a high risk of death before reaching
end-stage kidney disease. In order to allocate resources, such as advanced care nephrology where it is most needed, it
is essential to know which patients have the highest absolute risk of advancing to renal replacement therapy (RRT).
Methods: We included all nephrology-referred CKD stage 3b-5 patients in Sweden 2005–2011 included in the Swedish
renal registry (SRR-CKD) who had at least two serum creatinine measurements one year apart (+/− 6 months).
We followed these patients to either initiation of RRT, death, or September 30, 2013. Decline in estimated glomerular
filtration rate (eGFR) (%) was estimated during the one-year baseline period. The patients in the highest tertile
of progression (>18.7% decline in eGFR) during the initial year of follow-up were classified as “fast progressors”.
We estimated the cumulative incidence of RRT and death before RRT by age, eGFR and progression status
using competing risk models.
Results: There were 2119 RRT initiations (24.2%) and 2060 deaths (23.5%) before RRT started. The median progression
rate estimated during the initial year was −8.8% (Interquartile range [IQR] - 24.5–6.5%). A fast initial progression rate was
associated with a higher risk of RRT initiation (Sub Hazard Ratio [SHR] 2.24 (95% confidence interval [CI] 2.00–2.51) and
also a higher risk of death before RRT initiation (SHR 1.27 (95% CI 1.13–1.43). The five year probability of RRT
was highest in younger patients (<65 years) with fast initial progression rate (51% in CKD stage 4 and 76% in
stage 5), low overall in patients >75 years with a slow progression rate (7, 13, and 25% for CKD stages 3b, 4
and 5 respectively), and slightly higher in elderly patients with a fast initial progression rate (28% in CKD stage 4 and
47% in CKD stage 5) or with diabetic kidney disease.
Conclusions: The 5-year probability of RRT was low among referred slowly progressing CKD patients >75 years of age
because of the competing risk of death.
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Background
Chronic kidney disease (CKD) is a growing health problem;
the population prevalence has increased to an estimated
13% in the United States [1]. Although CKD affects all ages
there is a strong positive association with age: in individ-
uals over 70 years, prevalence is almost 50% [2]. With an
aging population, it may be difficult to identify which pa-
tients would benefit most from referral to and follow-up by
a nephrologist [3]. Many diagnosed with stable CKD stage
3 can be followed up by primary health care after the initial
nephrology evaluation. However, patients with advanced
kidney disease and a high risk for renal replacement ther-
apy (RRT) may benefit from nephrology care to facilitate
the necessary preparations for RRT such as timely fistula
surgery, if consistent with their preferences.
One risk factor for both RRT and death is a rapid de-
cline in renal function. It was recently found that patients
with renal function loss >30% over an initial period of two
years had a higher risk of end-stage renal disease (ESRD)
regardless of age and estimated glomerular filtration rate
(eGFR) [4]. However, this risk may differ in the “real-life”
setting of unselected patients referred to nephrology care
as opposed to patients included in various studies and
general population cohorts. Many elderly patients can
after a drop in eGFR, have stable eGFR levels for several
years without the need for dialysis initiation [5, 6]. In this
study we aimed to investigate the absolute risk of RRT as-
sociated with a slow versus rapid disease progression in a
nationally representative sample of nephrology-referred
patients taking into account the competing risk of death.
Methods
Study population
The Swedish Renal Registry (SRR) is one of the national
health data registries used to evaluate, control and com-
pare health care quality across the country [7, 8]. Swedish
Renal Registry - Chronic Kidney Disease (SRR-CKD) is the
part of SRR that includes patients referred to nephrology
clinics throughout Sweden. Clinics are urged to register pa-
tients when the renal function deteriorates ≤ 30 mL/min/
1.73 m2 with the option to register earlier if the local center
so wishes. We included all patients in the SRR-CKD, with
eGFR <45 ml/min/1.73 m2 and a baseline visit between
January 1, 2005 and December 31 2011. Patients were
followed until death, RRT-initiation or September 30, 2013,
whatever came first. At inclusion, patients received written
information about SRR and were permitted to refuse par-
ticipation in the registry. According to Swedish law, written
consent is not required because quality control is an inher-
ent element of hospital health care. The Regional Ethics
committee in Stockholm approved the study protocol. The
patient’s flow chart is presented in Fig. 1. The study
Fig. 1 Patient’s inclusion flow chart. RRT (renal replacement therapy), eGFR (estimated glomerular filtration rate), N (number), CKD (chronic kidney disease)
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adhered to the STROBE criteria for observational cohort
studies (Additional file 1).
Renal function decline
The vast majority of the creatinine measurements (98%)
were performed by enzymatic or corrected Jaffe method
both of which are traceable to isotope dilution mass spec-
trometry standards [9]. GFR was estimated from serum
creatinine by the CKD-EPI equation [10] and stratified per
CKD stages. Progression rate was measured as the differ-
ence (in %) between the first and last eGFR during a one-
year baseline period. For the second measurement, we se-
lected the serum creatinine closest to one-year allowing
measurements to vary within a six months range (thus the
baseline year ranged from 6 to 18 months). The values
were then rescaled to express the yearly % change. Pa-
tients without a second serum creatinine within this
period were excluded. Patients with a progression rate in
the highest tertile were considered “fast progressors” while
all others were considered “slow progressors”.
Clinical measures
The baseline measurements used for this analysis were all
obtained from the first visit of the follow-up, which oc-
curred after the initial one-year period when eGFR decline
was estimated (Additional file 2: Figure S1). The treating
nephrologist assigned the primary renal diagnosis; add-
itional comorbidity was obtained through linkage with the
National Patient Registry collecting information from all
hospitalizations in Sweden. Comorbidity was further classi-
fied into a Charlson comorbidity index score [11]. Since all
the patients had CKD, the minimum score was 2. There-
fore, we centered the score on the value 2, giving the score
the meaning of additional comorbidities to CKD. Blood
pressure and body mass index (BMI) were registered at the
first out-patient visit, together with the prescribed medica-
tions and treatment with a protein restricted diet (≤0.6 g/
kg/day). All laboratory measurements were collected as a
part of the regular clinical follow-up at different clinical
chemistry laboratories throughout Sweden. Although no
formal calibration was performed, the laboratories were all
monitored regularly by Equalis Sweden to assess the qual-
ity standards of the different analytical methods [9, 12].
Statistical analysis
Age was categorized as < 65, 65–75, and ≥ 75 years of age,
eGFR was categorized in CKD stages, BMI was categorized
according to WHO’s definition (<18.5, 18.5–25, 25–30,
>30 kg/m2), calcium and phosphate were included in cat-
egories of 0.1 units increase, while pulse pressure and mean
arterial pressure were used in categories of 10 mmHg in-
crease. Remaining continuous covariates were included as-
suming a linear effect on the outcome. There was a varying
proportion of missingness in our data. Most data had
missing values <10% whereas albumin-creatinine ratio
(ACR) had up to 65% missing and was only considered in
sensitivity analyses. We performed multiple imputation for
variables with up to 30% of missing values using multiple
imputation with chained equation [13]. We imputed nu-
meric variables using predictive mean-matching and binary
response variables using Bayesian logistic regression. The al-
gorithm iterated 30 times, and convergence was satisfactory.
Finally, 55 datasets were imputed and goodness of fit of the
whole procedure was evaluated and found to be good.
Being in a competing risks framework, the occurrence
of the event “death before RRT” impedes the occurrence
of the event “RRT initiation” and vice versa. Therefore,
we used ad hoc methods to analyze both outcomes.
First, we used Cox semiparametric models with Efron’s
method for ties to analyze the cause-specific hazards
treating subjects who experienced the competing event
as censored. Subsequently, we analyzed the sub-hazards
using Fine & Gray models [14] which were adjusted to
account for both left truncation and right censoring
[15]. We analyzed cause-specific hazards and sub-
hazards jointly with regard to both outcomes in order to
have a complete understanding of the event dynamics,
and of the association of the covariates with cause-
specific hazards and cumulative incidence functions
[16]. The included variables were those recorded at the
first follow-up visit after the initial one-year period, in-
cluding eGFR at inclusion and CKD-stage. Interactions
between age class, CKD stage and disease progression
were evaluated; significant interactions were retained in
the models used to estimate cumulative incidence func-
tions of event, discarded when presenting relative risk esti-
mates in order to ease interpretation. Goodness of fit of
the models was also evaluated, with particular attention
paid to the underlying proportionality assumption. No vi-
olations of the assumption were found in our analyses.
Finally, cause-specific probabilities of event at five years
were estimated from the cause-specific Cox models for
every possible combination of age class, CKD stage and
disease progression, and both outcomes, adjusting for the
median value (or most frequent, if categorical) of the
remaining covariates included in the models (male gender,
presence of hypertensive/ renovascular kidney disease,
BMI of 25–30 kg/m2, non-university clinic, no erythropoi-
etin stimulating agent use, no low protein diet, no statin
or iron use, use of diuretics and vitamin D, plus median
value of remaining laboratory data). These estimates were
produced for individuals with diabetic kidney disease as
well, everything else being equal. Analogously, cumulative
incidence function curves were produced using estimated
coefficients from the Fine & Gray models for every
possible combination of age class, CKD stage, disease
progression and outcome, adjusted for the remaining
covariates using their median or most frequent value.
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The analyses were performed using Stata 14.2 (Stata-




There were 13,542 patients with an outpatient visit dur-
ing the defined time-period. We excluded 1,653 patients
with age < 18 years, data errors, acute kidney injury or
eGFR ≥ 45 ml/min/1.73 m2. Of the remaining 11,889 pa-
tients, another 3,118 patients were excluded because of
missing progression rate (follow-up less than one year or
only one serum creatinine measurement within the pre-
specified time frame) (Fig. 1). The remaining cohort
consisted of 8,771 patients with a mean age of 72 years
and of whom 64% were men. Most of the patients were
diagnosed with hypertensive kidney disease (26%),
followed by diabetes nephropathy (20%), glomeruloneph-
ritis (10%), other specified causes (21%) and unknown
cause of uremia (23%). The majority of the patients were
in CKD stage 4 and the median eGFR was 20.2 ml/min/
1.73 m2 after the initial one-year baseline period.
Progression rate
The median progression rate estimated during the initial
year was −8.8% (Interquartile range [IQR] -24.5 − 6.5%)
or an absolute median decline by −1.71 ml/min/1.73 m2
(IQR −4.81 – 1.33). Even though most of the patients
experienced deteriorating renal function, a substantial
proportion (35.1%) had no change or an improvement in
eGFR during the first year. Patients defined as fast pro-
gressors (highest tertile, > −18.7% decline/year) were
younger, had lower eGFR at baseline, lower hemoglobin,
higher ACR, and higher phosphate compared with pa-
tients who were defined as non-progressors (Table 1).
Mortality
Median follow-up time after the initial year was 2.8 years,
(IQR 1.7 − 3.9 years). There were 2,060 deaths (23.5%)
recorded before RRT was initiated during follow-up. Pa-
tients >75 years of age had almost six times higher risk
of death before RRT was initiated compared with pa-
tients less than 65 years (Table 2). Variables associated
with lower risk of death before RRT were female sex,
BMI > 30 kg/m2 and having diabetic kidney disease or
glomerulonephritis compared with hypertensive kidney
disease. Patients classified as “fast progressors” had a
higher pre-dialysis mortality (Sub-hazard ratio [SHR]
1.27; 95% CI 1.13–1.43). However, the absolute risk of
death before RRT was not very different in fast progres-
sors as compared with slow progressors except for pa-
tients > 75 years of age with CKD stage G5 (Fig. 2).
Initiation of renal replacement therapy
Almost one-fourth (24.2%) of all patients initiated RRT
while 52.4% were event-free at the end of the follow-up
period. Taking the competing risk of death into account
the most important risk factors of RRT initiation was
lower CKD stage, lower age, and a fast one-year progres-
sion rate (Table 2). Higher comorbidity score and dia-
betic kidney disease relative to hypertensive kidney
disease was associated with higher RRT incidence. Also,
women had a much lower incidence of RRT (SHR 0.72;
95% CI 0.66–0.80) compared with men in the exten-
sively adjusted final model.
The cumulative risk of RRT decreased by age and in-
creased by CKD stage among both slow and fast pro-
gressors (Fig. 2). Patients characterized as fast
progressors had a markedly higher cumulative risk of
RRT in all age groups and CKD stages. The only patients
in the slowly progressing group who had close to 50%
cause-specific risk of RRT within five years were those
younger than 65 years in stage 5 (Fig. 3), while among
fast progressors even higher risk was observed among all
patients <75 years (stage 5) and <65 years (stage 4–5).
Slowly progressing patients above 75 years of age had a
low risk of RRT regardless of CKD stage (25% for pa-
tients in CKD stage 5, 13% for patients in CKD stage 4),
while elderly (>75 years) fast progressors in CKD stage 5
had a 47% risk of RRT within 5 years. Even though dia-
betic patients had a higher risk of RRT compared with
patients with hypertensive kidney disease (SHR of 1.33,
95% C.I. of 1.13–1.56), this did not translate into a big
difference in absolute risk of RRT (Additional file 2:
Figure S2). Patients who were >75 years with a slow
progression rate always had greater risk for death
than start of RRT regardless of renal function, while
patients <65 years of age had higher or equally high
risk of RRT compared with death before RRT regard-
less of renal function and progression rate (Fig. 4).
Finally, we performed sensitivity analyses in patients
with information on albuminuria: the overall coefficients
from both cause-specific and competing risks models
were consistent with the main analysis for both mortality
and risk of RRT.
Discussion
In this nationwide study of unselected, representative
nephrology care patients in Sweden with eGFR <45 ml/
min/1.73 m2 we found that clinical characteristics such
as age, sex and CKD stage greatly influenced the risk of
RRT and mortality before RRT initiation. Further, the
preceding one-year progression rate was an important
indicator of the future RRT risk. In general, elderly pa-
tients classified as slow progressors in our study had a
low risk of RRT (about 25% within 5 years in CKD
stage G5), while elderly with a fast progression still had
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much lower RRT risk than the younger patient of simi-
lar CKD stage.
Some previous studies have shown that both age and
CKD stage influence the risk of RRT, but also that there is
a strong interaction between them because of the compet-
ing risk of death [3, 17]. The two largest of these studies
were performed in different clinical settings (O’Hare [17]
used a cohort of American Veterans, whereas De Nicola
[3, 18] used nephrology- referred patients in a geograph-
ical region in Italy). In the US-based study, the risk of
mortality before RRT initiation was higher compared with
the Italian study. The results of our study in Swedish
nephrology-referred patients, however, demonstrated a
high mortality before RRT initiation in line with the study
by O’Hare [17]. It has been suggested that differences in
RRT risk are attributed to the population background;
Table 1 Demographics by disease progression in a national,
representative cohort of referred patients with chronic kidney
disease
Demographics Progressors
N = 2,924 (33.3%)
Non-progressors
N = 5,847 (66.6%)
Age, median 69.9 (59.3–78.7) 73.4 (64.2–80.6)
<65 years 1,091 (37.3%) 1,568 (26.8%)
65- < 75 years 767 (26.2%) 1,683 (28.8%)
≥75 years 1,066 (36.5%) 2,596 (44.4%)
Men 1,931 (66.0%) 3,670 (62.8%)
Primary renal disease
Hypertension/renovascular 732 (25.0%) 1,538 (26.3%)
Diabetes nephropathy 721 (24.7%) 1,071 (18.3%)
Glomerulonephritis 315 (10.8%) 600 (10.3%)
Other specified disease 618 (21.1%) 1,199 (20.5%)
Unknown 538 (18.4%) 1,439 (24.6%)
Progression rate (% decline in
ml/min/1.73 m2 per year)
−31.9 (−43.9––24.5) 0.60 (−8.8–14.6)
Progression rate (absolute change
in ml/min/1.73 m2 per year)
−6.1 (−8.6––4.3) 0.13 (−1.8–3.0)
Chronic Kidney Disease Stage
G3b 56 (1.9%) 1,434 (24.5%)
G4 1,117 (38.2%) 3,570 (61.1%)
G5 1,751 (59.9%) 843 (14.4%)
Comorbidity at baseline
Diabetes 1,172 (40.1%) 2,118 (36.2%)
Cardiovascular disease 1,109 (37.9%) 2,205 (37.7%)
Dementia 24 (0.8%) 57 (1.0%)
Chronic pulmonary disease 217 (7.4%) 483 (8.3%)
Cancer 414 (14.2%) 1,011 (17.3%)
Charlson score above kidney
disease median (IQR)
1.0 (0.00–2.0) 1.0 (0.0–2.0)
Current medication
ESA use [n = 7221] 680 (23.3%) 1,062 (18.2%)
Antihypertensives number
of, median (IQR)
3.0 (2.0–4.0) 3.0 (2.0–4.0)
Protein restricted diet use 436 (14.9%) 545 (9.3%)
Diuretics use 2,148 (73.5%) 3,974 (68.0%)
Statin use 1,311 (44.8%) 2,727 (46.6%)
Vitamin-D supplements use 1,770 (60.5%) 3,005 (51.4%)
Iron use
intravenous 286 (9.8%) 425 (7.3%)
oral 524 (17.9%) 853 (14.6%)
Laboratory data
P-Albumin (g/l): [n = 8177] 36.0 (33.0–39.0) 37.0 (35.0–40.00=)
S-Calcium (mmol/l): [n = 7578] 2.28 (2.17–2.37) 2.31 (2.23–2.39)
CRP (mmol/l): [n = 5723] 5.0 (2.8–10.0) 5.0 (2.5–10.0)
Table 1 Demographics by disease progression in a national,




1.5 (1.3–1.8) 1.2 (1.1–1.4)
S-Creatinine (mmol/l): 355 (272–475) 217 (177–268)
B-Hemoglobin (g/l): [n = 8537] 117 (108–127) 125 (116–135)
S-PTH (ng/ml): [n = 5818] 21.0 (12.9–33.7)) 14.2 (9.5–21.8)
U-Albumin/creatinine ratio
(mg/mmol) [n = 3149]
40.1 (9.4–170.9) 12.0 (2.5–48.0)
eGFR (ml/min/1.73 m2): 13.3 (9.4–18.2) 23.6 (18.0–29.9)
Clinical information
Mean arterial pressure
(median mmHg, IQR) [n= 8159]
97.6 (90.0–106.6) 96.0 (88.3–103.3)
Pulse pressure (median mmHg,
IQR) [n = 8159]
60.0 (50.0–75.0) 60.0 (49.0–70.0)
BMI (IQR) [n = 6432]
<18.5 Kg/m2 27 (0.9%) 61 (1.0%)
18.5–25 Kg/m2 733 (25.1%) 1,344 (23.0%)
25–30 Kg/m2 781 (26.7%) 1,630 (27.9%)
>30 Kg/m2 640 (21.9%) 1,216 (20.8%)
Region
Lower North 676 (23.1%) 1,319 (22.6%)
South 405 (13.9%) 777 (13.3%)
Southeast 356 (12.2%) 600 (10.3%)
Southwest 514 (17.6%) 1,166 (19.9%)
Upper North 151 (5.2%) 269 (4.6%)
Stockholm 822 (28.1%) 1,716 (29.4%)
University Hospital 1,192 (40.8%) 2,381 (40.7%)
All categorical values are expressed as numbers (n) and percentage (%). All
continuous variables are expressed as median and interquartile range (IQR).
Erythropoietin stimulating agents (ESA), estimated glomerular filtration rate
(eGFR), Serum (S), Plasma (P), Blood (B), and Urine (U). To convert Calcium in
mmol/l to mg/dL divide by 0.2495. To convert Phosphate mmol/l to mg/dL
multiply with 3.0974. To convert Hemoglobin in g/l to g/dL divide by 10. To
convert creatinine from micromole/l to mg/dL multiply by 0.0113
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general population cohorts have overall lower end-stage
kidney disease risk as compared with specialized care co-
horts [4, 19]. However, our results suggest that the risk of
RRT and end-stage kidney disease does not only depend
on general versus referred population but also on other
factors. These factors could be underlying population
mortality (there is a strong north-south cardiovascular dis-
ease risk gradient across Europe [20] which may explain
the higher mortality before RRT in Sweden versus Italy),
or they could instead reflect differences in attitude to-
wards initiating dialysis in elderly individuals [21], tim-
ing of dialysis initiation [22] or referral pattern [23].
For example, a recent comparison of the performance
of the kidney failure risk equation demonstrated that
there were quite substantial differences in the risk for
end-stage kidney disease between various cohorts in
Europe and the US [24].
Decline in renal function has been associated with in-
creased cardiovascular mortality [25] and initiation of
RRT [26]. In younger individuals, low eGFR per se is
more predictive of end-stage kidney disease since it is
more often the result of a specific kidney disease as
compared with elderly where it is more often a marker
of age-related conditions [17]. Recently Coresh and co-
workers demonstrated the importance of a rapid pro-
gression rate and suggested that a decline in GFR of 30%
over two years could be used as an end-point in clinical
trials [4]. Our study is in agreement with these data, and
indicates that also in elderly individuals the progression
rate influences the risk of RRT but not the competing
risk of death to the same extent. However, the absolute
risk of RRT is still extensively influenced by the compet-
ing risk of death in elderly individuals, also under the
circumstance of a fast progression rate - in our data
shown as a decreasing absolute risk difference with age.
It has been proposed that trajectories of renal function
could be used to predict timely RRT planning [27]. In
addition, early referral to a nephrologist is associated
with better survival [24, 28] and more timely preparation
for dialysis care. However, it is equally important that
the resources of nephrology care are directed to where it
is most needed. Our results indicate that continued
Table 2 Sub hazard ratios for initiation of renal replacement therapy and death before initiation of renal replacement therapy in a
nationwide representative referred cohort of chronic kidney disease patients
Demographics RRT initiation Death before RRT initiation
SHR 95% CI P-value SHR 95% CI P-value
Age (years)
<65 1.00 ref 1.00 ref
65–75 0.64 0.57–0.72 <0.01 2.48 2.07–2.97 <0.01
>75 0.449 0.40–0.51 <0.01 5.47 4.61–6.49 <0.01
Women 0.72 0.66–0.80 <0.01 0.77 0.70–0.85 <0.01
Primary renal disease
Hypertensive kidney disease 1.00 ref 1.00 ref
Diabetes nephropathy 1.21 1.03–1.41 0.020 0.57 0.45–0.72 <0.01
Glomerulonephritis 1.04 0.91–1.19 0.59 0.78 0.67–0.90 <0.01
Other specified disease 0.67 0.57–0.78 <0.01 1.06 0.94–1.19 0.36
Unknown 1.00 0.97–1.04 0.87 1.20 1.17–1.24 <0.01
Fast progressor (above 18.7% decline/year) 2.24 2.00–2.51 <0.01 1.27 1.13–1.43 <0.01
CKD stagea
G3b 1.00 ref 1.00 ref
G4 2.04 1.52–2.75 <0.01 0.94 0.80–1.09 0.40
G5 4.05 2.89–5.67 <0.01 0.94 0.75–1.19 0.61
Charlson Score above kidney disease (per 1 unit increase) 1.15 1.04–1.28 0.01 1.06 0.95–1.17 0.31
Body Mass Index (kg/m2)
<18.5 1.08 0.72–1.62 0.72 1.39 0.98–1.96 0.06
18.5–25 1.00 ref 1.00 ref
25–30 0.91 0.81–1.02 0.11 0.96 0.85–1.07 0.46
>30 0.90 0.80–1.02 0.11 0.86 0.76–0.98 0.02
Chronic Kidney Disease (CKD) Renal replacement therapy (RRT), Sub-hazard ratio (SHR) Confidence interval (CI). All variables, estimates are adjusted for all other
variables, eGFR after the initial follow-up, current medication, laboratory data, hospital status, region and diet
aafter the initial one-year baseline period when progression rate was estimated
















































Event−free CIF: Death CIF: ESRD
Fig. 2 Cumulative incidence function for renal replacement therapy (blue) and death before renal replacement therapy (orange) by age, chronic
kidney disease stage, and disease progression rate for patients under nephrology care. The cumulative incidence function was adjusted for the
remaining covariates using their median value if numeric or most frequent value if categorical. On the Y-axis is cumulative incidence stratified by
three CKD stages. On the X-axis is the time from inclusion in years, stratified by age category and progression status after the initial baseline period
Fig. 3 Five-year cause-specific probabilities of renal replacement therapy and death before renal replacement therapy for hypertensive kidney
disease patients with a fast and slow progression rate stratified by age and chronic kidney disease stage. CKD (chronic kidney disease) categorized
according to KDIGO classification system
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follow-up at the nephrology unit is most important for
younger CKD patients, especially those with a fast pro-
gression rate who also exhibits a high absolute risk of
RRT start within 5 years. In elderly patients (>75 years of
age) the 5-year risk of RRT is low-moderate also at ad-
vanced stages of CKD and the 5-year risk of RRT is es-
pecially low in those with a slow progression rate. Thus,
elderly slow progressors in CKD stage 3b-4 who do not
suffer any major metabolic disturbances could be re-
ferred to primary health care with the proviso that they
should be returned to the nephrology clinic if they pro-
gress to CKD stage 5 where the risk of future RRT in-
creases. In these elderly patients, timely access planning
also has to be weighed against the risk of dying with a
functioning fistula before or shortly after RRT initiation
since mortality continues to be high also the year after
dialysis start [29].
Our study has several strengths. It is the first study to
use a national, representative cohort under stable nephrol-
ogy care, where the treating nephrologists provided the
primary renal diagnoses, and where clinical information
was available both at inclusion and follow-up. Due to the
use of linkages to national registries and the unique per-
sonal identity number of all Swedish citizens there were
no losses of follow-up. The health-care system in Sweden
is tax-funded, and there are no major differences in inci-
dence of RRT throughout the country [30]. Our study also
has some limitations. Although 96% of the nephrology
units in Sweden send data to the SRR-CKD, it has been
estimated that about 76% of all nephrology-referred CKD
stage 4–5 patients are included in the registry [7]. In earl-
ier CKD stages (3b), the completeness is unknown, since
it is not mandatory to use the registry until eGFR drops
below 30 ml/min/1.73 m2. However, registrations should
be systematic within each clinic, and bias due to selection
would be possible only if clinics registering patients
already at CKD stage 3 differ in their RRT initiation policy
or mortality from those who do not. Another limitation is
that we excluded patients with less than two creatinine
measurements or who died within one year. Thus, our re-
sults are only generalizable to patients under stable neph-
rology care for more than one year. When considering all
patients referred to nephrology care, the risk of death be-
fore RRT initiation may be even higher. Furthermore,
ACR was not measured in all the patients since it was not
a mandatory variable in the registry until 2013. The asso-
ciations between ACR, progression and mortality are well
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Fig. 4 Contribution of each competing event (renal replacement therapy and death) to the overall risk of an event at any time during follow-up.
The area represents the contribution of each competing event to the overall risk of event at any time. The dashed horizontal line at 50% is the
equivalence of contributions line
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study, adding ACR did not substantially affect our results
regarding mortality. In addition, the progression rate
would in itself consider some of the effect of ACR. Further
research is needed to investigate whether adding progres-
sion rate as a predictor to the kidney failure risk equation
could improve its performance and maybe explain some
of the variation in incidence of RRT between the different
CKD cohorts.
Conclusions
In this nationwide registry study of 8,771 referred pa-
tients with CKD stage 3b-5, the risk of RRT was high in
younger patients with fast initial progression rate. Fur-
thermore, the cumulative incidence of RRT was gener-
ally low among elderly, slowly progressing patients even
in advanced CKD stages. Thus, for planning, treating
and preparing the right patients for RRT, following the
slope of eGFR is important.
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